Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome
Effect of Early Application of Recombinant Human Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
A PHASE3 clinical study on Cerebral Palsy and Intracranial Hemorrhages, this trial is ongoing. The trial is conducted by First Affiliated Hospital Xi'an Jiaotong University and has accumulated 10 data snapshots since 2017. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Oct 2021 — Nov 2022 [monthly]
Unknown Status PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Unknown Status PHASE3
▶ Show 5 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Sep 2018 — Oct 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital Xi'an Jiaotong University
- Northwest Women's and Children's Hospital, Xi'an, Shaanxi
- Second Affiliated Hospital of Xi'an Jiaotong University
- Shaanxi Provincial People's Hospital
- Tang-Du Hospital
- Xi'an No.4 Hospital
- Xian Children's Hospital
- Xijing Hospital
For direct contact, visit the study record on ClinicalTrials.gov .